The KDM5D Knockout KYSE-150 Polyclonal Cells product comprises a CRISPR/Cas9-edited polyclonal knockout cell population in which the KDM5D gene has been disrupted in the KYSE-150 human esophageal squamous cell carcinoma line. This heterogeneous cell pool, generated through CRISPR/Cas9-mediated genome editing, enables loss-of-function analysis of KDM5D in a model system derived from a well-differentiated esophageal squamous cell carcinoma.
The KYSE-150 cell line was established from a well-differentiated human esophageal squamous cell carcinoma and is extensively used to study the molecular mechanisms underlying this malignancy. It retains key features of the original tumor and provides a relevant cellular context for investigating epigenetic regulators such as histone demethylases.
KDM5D encodes a histone lysine demethylase that specifically removes di- and tri-methyl groups from histone H3 at lysine 4 (H3K4me2/me3), thereby acting as a transcriptional repressor. It interacts with HDAC1 and HDAC2 within chromatin remodeling complexes, including the REST co-repressor, and is regulated by the androgen receptor and retinoic acid receptors. Its demethylase activity modulates expression of downstream targets such as HOX genes, CDH1, and SNAI2, linking KDM5D to gene programs controlling differentiation and epithelial-mesenchymal transition.
In KYSE-150 cells, KDM5D knockout is expected to elevate H3K4 methylation at target loci, derepressing genes normally silenced by the enzyme and altering chromatin states. This epigenetic perturbation may influence cancer-relevant phenotypes, consistent with the reported involvement of KDM5D in esophageal squamous cell carcinoma, prostate cancer, and gastric cancer. The polyclonal knockout pool offers a robust platform to analyze how KDM5D loss affects transcription, chromatin dynamics, and cellular behaviors linked to tumor progression.
This product is suitable for functional studies of KDM5D in esophageal cancer biology, epigenetic regulation, and drug target validation for demethylase inhibitors. It supports a variety of experimental techniques, including Western blotting for KDM5D and histone modifications, RT-qPCR, ChIP-qPCR for H3K4me3, RNA-seq, immunofluorescence, and cell-based proliferation, migration/invasion, and drug sensitivity assays. For further information, technical assistance, or custom requests, please contact Ascent Research.
